Philips to Showcase Newly FDA-Cleared Cardiovascular Workspace at RSNA

The Food and Drug Administration (FDA) has granted 510(k) clearance for the Cardiovascular Workspace (IntelliSpace Cardiovascular) software, which may facilitate improved efficiency in the interpretation and reporting of cardiovascular imaging.

Providing software as a service (SaaS) deployment through the cloud, the Cardiovascular Workspace (available through the Philips HealthSuite platform) fosters streamlined imaging workflows, according to Philips, the manufacturer of the Cardiovascular Workspace.

In addition to secure remote access to patient data and imaging, Philips noted the Cardiovascular Workspace (which will be showcased at the upcoming RSNA conference) provides automated data synchronization with a vendor-neutral archive (VNA) to allow smoother multidisciplinary collaboration in cardiovascular care. Through cloud modernization, the company added that the Cardiovascular Workspace enables the development and integration of advanced AI applications.

“Our cloud-enabled Cardiovascular Workspace provides the foundation for future AI-enabled tools and workflow insights across the cardiology care continuum,” said Madhuri Sebastian, the business leader of imaging informatics at Philips. “With cloud deployment, we are enabling secure remote reading and improving efficiency. Our approach is a true differentiator because it unlocks the ability to scale and innovate through large datasets. This is how Philips is helping health systems deliver smarter, more connected cardiovascular care.”

(Editor’s note: The annual Radiological Society of North America (RSNA) conference will be held November 30 to December 4 in Chicago.)